Mölnlycke integrated Annual Report 2023
Today we are delighted to announce the launch of the Mölnlycke integrated Annual Report 2023. Our dedication to revolutionising care for people and planet contributed to a very successful year with record high annual net sales of EUR 1,924 million and substantial improvements in profitability. We continue to report our sustainability achievements in accordance with the Global Reporting Initiative (GRI) standards.

Performance highlights
Mölnlycke reported strong growth in 2023, with net sales reaching EUR 1,924 million, an 8% increase in constant currency rates. The EBITDA grew by 14% to EUR 545 million, reflecting substantial organic growth and market share gains across most markets.
Sustainability achievements
We made significant strides in operationalising our sustainability roadmap 2030. Mölnlycke’s near-term greenhouse gas emission reduction targets were validated by the Science Based Targets initiative. Noteworthy progress was made in our journey towards 100% fossil-free electricity by the end of 2024, with 61% fossil-free electricity share in 2023. We also achieved a 20% reduction in overall absolute greenhouse gas emissions across the entire value chain compared to the 2021 baseline. Finally, we expanded the scope of Life Cycle Assessment to cover 30% of our portfolio in terms of net sales.

"In 2023 we continued to execute on a strategy firmly rooted in customer research and pivoted to lead in sustainable, digital and customer-centric healthcare. With strong growth and substantial improvements in profitability, I am confident that we are on the right track".
Zlatko Rihter Chief Executive Officer
Innovation and quality highlights
To enhance surgical performance, Mölnlycke introduced hand scanning technology using artificial intelligence and machine learning for optimal glove fit, launched Mepilex® Up in the US, upgraded the Mepilex® Border Post-Op product family globally and registered Hibiwash®, - the new colour- and fragrance-free Hibi formula. We also successfully completed the transition to Medical Device Regulation (MDR), one of the first MedTech companies to do so.
Strategic investments
Mölnlycke secured long-term financing through a EUR 400 million Eurobond and a EUR 350 million Revolving Credit Facility. We also decided to invest EUR 60 million to increase production capacity, including a new Mepilex Border Flex production line and a new Ethylene Oxide sterilisation unit in Finland.
Latest news
-
Mölnlycke awarded second consecutive EcoVadis Platinum medal for sustainability performance
Gothenburg, Sweden. 21 August 2025. Mölnlycke®, a world-leading MedTech company, has once again been recognised as a global sustainability leader, earning the prestigious EcoVadis Platinum medal for the second year in a row.
-
New study highlights the importance of double gloving with indicator systems
A new peer-reviewed study published in the Journal of Hospital Infection underscores the critical role of double gloving and indicator systems in reducing the risk of undetected glove breaches during surgery.
-
Mölnlycke Health Care makes record investment to increase global manufacturing capacity with expansion in Maine, USA
Gothenburg, Sweden, 26 June 2025. Mölnlycke Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
-
Mölnlycke Health Care secures USD 400 Million in financing from SEK to support global expansion strategy
Stockholm/Gothenburg – 24 June, 2025. Mölnlycke Health Care and The Swedish Export Credit Corporation (SEK) have signed a USD 400 million financing agreement to support the healthcare company’s continued global growth and development.
-
Mölnlycke advocates a holistic approach to healthcare sustainability
New white paper calls for integration of environmental, human and economic metrics in sustainability assessments of medical technologies.
-
Mölnlycke Health Care unveils new headquarters at GoCo Health Innovation City, marking a new era of collaboration and innovation
-
Tamer Mölnlycke Care celebrates a new chapter in healthcare in the Kingdom of Saudi Arabia
-
Filippa Stenberg joins Mölnlycke Board of Directors
-
Mölnlycke Health Care inaugurates new global headquarters at GoCo Health Innovation City
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.